Dr. Inna Sominsky M.D.

Media Releases

Get to know Hematologist-Oncologist Dr. Inna Sominsky, who serves patients in Brooklyn, New York.

Dr. Sominsky is a board-certified hematologist-oncologist in practice at Hematology Oncology Associates of Brooklyn. Recognized by the American Society of Clinical Oncology, Hematology Oncology Associates of Brooklyn is a state-of-the-art cancer treatment center, focused on caring for patients with malignancy, blood disorders, and immunology abnormalities. Patients can be confident that they will receive competent, cutting-edge care delivered by a skilled and compassionate team of providers whose mission is to ensure the best possible clinical outcome.

Professionally, she is also affiliated with Maimonides Medical Center, a non-profit, non-sectarian hospital located in Brooklyn, New York. Maimonides is both a treatment facility and an academic medical center with 711 beds, and more than 70 primary care and subspecialty programs.

A 1995 graduate of the Kursk State Medical University in Kursk, Russia, Dr. Sominsky relocated to the United States for training. She completed her internship and residency in internal medicine at Maimonides Medical Center from 1999 to 2002, followed by her fellowship in hematology and medical oncology at the same educational venue from 2004 to 2007. 

Thereafter, she became board-certified in hematology and medical oncology by the American Board of Internal Medicine, a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist, like Dr. Sominsky, is a physician who specializes in the diagnosis, treatment, or prevention of blood diseases and cancers such as iron-deficiency anemia, hemophilia, sickle-cell disease, leukemia, and lymphoma. 

Recommended Articles

• Teen Treated for Lymphoma to Play College Baseball

  Whether it’s the Dodgers or the Red Sox or the local high school team, they’re called ‘the boys of summer’.While summer is when the teams begin competitive play, they are very much the boys of spring as well.The temperature might be cool, but the air is sweet with promise.The players pull...

• Nurse Donates Breast Milk for Lymphoma Patient's Baby

  Ashley Chestnut, a mother of two children from La Vista, Nebraska, was breastfeeding her 5-month-year-old son Easton when she began to experience a sharp and sudden pain in her shoulder and chest. “All of a sudden a sharp pain in my shoulder and chest, it was like hitting a freight train. It was...

• Facts About Multiple Myeloma

  Multiple myeloma is a certain form of cancer of the plasma cell, which is part of the immune system. It initiates in the bone marrow, where the blood cells are produced.The immune system is made of variety of cells that fight infections and keep the body healthy. What takes place in bone marrow...

• Potential Causes of Leukopenia

  IntroductionA decrease in the number of white blood cells (WBCs) is referred to as leukopenia. There are several causes for leukopenia. It may be due to certain drugs, cancer, radiation and chemotherapy for cancer, stem cell transplant, surgery, steroids, or autoimmune disorders. The immune system...

• Make-A-Wish Makes a Movie Star

  Through their fundraising, on average in the United States and its territories, Make-A-Wish is able to grant the wish of a child every 34 minutes.How was it started?The Make-A-Wish Foundation started with the wish of one 7-year-old boy’s wish in 1980. Chris Grecius, who had leukemia, wanted to be...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...